Showing results (301-310 of 334) with videos related to

Sort By:
Pageof 34
Blood|June 8, 2017
Outcome of children with acute leukemia given HLA-haploidentical HSCT after αβ T-cell and B-cell depletionFranco Locatelli, Pietro Merli, Daria Pagliara, et al.
Eclinicalmedicine|December 17, 2024
Maintenance therapy with trofosfamide, idarubicin and etoposide in patients with rhabdomyosarcoma and other high-risk soft tissue sarcomas (CWS-2007-HR): a multicentre, open-label, randomised controlled phase 3 trialEwa Koscielniak, Gustaf Ljungman, Bernarda Kazanowska, et al.
International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group|January 11, 2020
Systemic antitumor effect by regional hyperthermia combined with low-dose chemotherapy and immunologic correlates in an adolescent patient with rhabdomyosarcoma - a case reportRolf D Issels, Lars H Lindner, Michael von Bergwelt-Baildon, et al.
Bone Marrow Transplantation|December 25, 2021
Results of a multicenter phase I/II trial of TCRαβ and CD19-depleted haploidentical hematopoietic stem cell transplantation for adult and pediatric patientsWolfgang A Bethge, Matthias Eyrich, Stephan Mielke, et al.
Frontiers in Immunology|August 9, 2021
Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody TreatmentChristian Martin Seitz, Tim Flaadt, Markus Mezger, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 26, 2016
Proceedings from the Second Haploidentical Stem Cell Transplantation Symposium-Haplo2014, San Francisco, California, December 4, 2014Monzr M Al Malki, Mary Horowitz, Rupert Handgretinger, et al.
Oncoimmunology|July 4, 2015
Cancer-targeted IL-12 controls human rhabdomyosarcoma by senescence induction and myogenic differentiationKarin Schilbach, Mohammed Alkhaled, Christian Welker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 9, 2014
Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastomaFariba Navid, Paul M Sondel, Raymond Barfield, et al.
Blood|August 2, 2019
LMO2 activation by deacetylation is indispensable for hematopoiesis and T-ALL leukemogenesisTatsuya Morishima, Ann-Christin Krahl, Masoud Nasri, et al.
Leukemia|August 2, 2024
Rational combinatorial targeting by adapter CAR-T-cells (AdCAR-T) prevents antigen escape in acute myeloid leukemiaDaniel Atar, Lara Ruoff, Anna-Sophia Mast, et al.
Pageof 34